Roche Holding AG Shares Outstanding 2006-2018 | RHHBY

Roche Holding AG shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Roche Holding AG shares outstanding for the quarter ending December 31, 2018 were M, a NAN% increase year-over-year.
  • Roche Holding AG 2018 shares outstanding were 6.88B, a 0% decline from 2017.
  • Roche Holding AG 2017 shares outstanding were 6.88B, a 0% decline from 2016.
  • Roche Holding AG 2016 shares outstanding were 6.88B, a 0.25% decline from 2015.
Roche Holding AG Annual Shares Outstanding
(Millions of Shares)
2018 6,880
2017 6,880
2016 6,880
2015 6,897
2014 6,906
2013 13,808
2012 13,676
2011 6,807
2010 7,035
2009 6,905
2008 4,158
2007 4,027
2006 4,053
2005
Roche Holding AG Quarterly Shares Outstanding
(Millions of Shares)
Q4 2018
Q2 2018
Q4 2017
Q2 2017
Q4 2016
Q2 2016
Q4 2015
Q2 2015
Q4 2014
Q2 2014
Q4 2013
Q2 2013
Q4 2012
Q2 2012
Q4 2011
Q2 2011
Q4 2010
Q2 2010
Q4 2009
Q2 2009
Q4 2008
Q2 2008
Q4 2007
Q3 2007 406
Q2 2007
Q4 2006
Q2 2006
Q4 2005
Q2 2005
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $282.158B $58.120B
Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.359B 17.09
Pfizer (PFE) United States $220.369B 13.10
Merck (MRK) United States $218.904B 16.96
Novartis AG (NVS) Switzerland $215.131B 18.16
Novo Nordisk (NVO) Denmark $144.638B 24.93
Eli Lilly (LLY) United States $133.525B 24.66
AstraZeneca (AZN) United Kingdom $129.299B 23.35
AbbVie (ABBV) United States $123.541B 9.68
Sanofi (SNY) France $122.027B 14.99
GlaxoSmithKline (GSK) United Kingdom $117.802B 14.27
Bristol-Myers Squibb (BMY) United States $104.535B 14.61
Bayer (BAYRY) Germany $77.588B 11.49
H Lundbeck (HLUYY) Denmark $8.147B 14.16